The relationship between HER2 overexpression and angiogenesis in gastric cancer

被引:19
作者
Ciesielski, Maciej [1 ,2 ]
Szajewski, Mariusz [1 ,2 ]
Peksa, Rafal [3 ]
Lewandowska, Marzena Anna [4 ]
Zielinski, Jacek [5 ]
Walczak, Jakub [1 ]
Szefel, Jaroslaw [1 ,2 ]
Kruszewski, Wieslaw Janusz [1 ,2 ]
机构
[1] Gdynia Oncol Ctr, Dept Surg Oncol, Gdynia, Poland
[2] Med Univ Gdansk, Div Propedeut Oncol, Gdansk, Poland
[3] Med Univ Gdansk, Dept Pathomorphol, Gdansk, Poland
[4] Lukaszczyk Oncol Ctr, IFM, Mol Oncol & Genet Dept, Bydgoszcz, Poland
[5] Med Univ Gdansk, Dept Oncol Surg, Gdansk, Poland
关键词
CD34; ErbB-2; neovascularization; stomach neoplasms; ENDOTHELIAL GROWTH-FACTOR; MICROVESSEL DENSITY; DOUBLE-BLIND; FACTOR-C; EXPRESSION; THERAPY;
D O I
10.1097/MD.0000000000012854
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In gastric cancer, HER2 protein overexpression is considered to be conducive to the higher proliferation activity of the tumor cells. Tumor formation is associated with angiogenesis in order to secure an abundant supply of oxygen and glucose to cancer cells. The aim of the study was to assess if HER2 overexpression is related to higher microvessel density (MVD) in the tumor stroma. The archival samples of primary tumor from 144 consecutive patients that underwent gastric resection for cancer between August 1, 2006 and December 31, 2013 in the Department of Oncological Surgery of Medical University of Gdansk were analyzed. CD34 was used as a marker of MVD in the tumor stroma. Both CD34 and HER2 protein expressions were tested by immunohistochemistry. The assays were unsuccessful to estimate HER2 in 10 cases and CD34 in 14 cases due to technical reasons. The results were obtained for 128 patients. HER2 0 and HER2 1+ were considered negative, while HER2+ and HER2 3+ were recognized as positive. Mean MVD (mean number of vessels in the visual field) was 32.4 (median 29.5). Microvessel density was insignificantly higher in HER2 positive tumors. The slight difference was also seen between IHC 2+ and 3+ groups. The differences did not reach the level of statistical significance. Statistical analysis performed in our study did not reveal the significant relationship between HER2 overexpression on the tumor cells and MVD in the tumor stroma.
引用
收藏
页数:6
相关论文
共 24 条
  • [1] Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges
    Alameddine, Raafat S.
    Otrock, Zaher K.
    Awada, Ahmad
    Shamseddine, Ali
    [J]. CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 313 - 324
  • [2] Badescu A, 2012, ROM J MORPHOL EMBRYO, V53, P997
  • [3] Gastric biomarkers: a global review
    Baniak, Nick
    Senger, Jenna-Lynn
    Ahmed, Shahid
    Kanthan, S. C.
    Kanthan, Rani
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [4] HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
    Bartley, Angela N.
    Washington, Mary Kay
    Colasacco, Carol
    Ventura, Christina B.
    Ismaila, Nofisat
    Benson, Al B., III
    Carrato, Alfredo
    Gulley, Margaret L.
    Jain, Dhanpat
    Kakar, Sanjay
    Mackay, Helen J.
    Streutker, Catherine
    Tang, Laura
    Troxell, Megan
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 446 - +
  • [5] HER2-positive gastric cancer
    Boku, Narikazu
    [J]. GASTRIC CANCER, 2014, 17 (01) : 1 - 12
  • [6] The HER2 Gene and HER2 Protein Status and Chromosome 17 Polysomy in Gastric Cancer Cells in Own Material
    Ciesielski, Maciej
    Kruszewski, Wieslaw Janusz
    Smialek, Urszula
    Walczak, Jakub
    Szajewski, Mariusz
    Szefel, Jaroslaw
    Wydra, Jacek
    Kawecki, Krzysztof
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (02) : 113 - 117
  • [7] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [8] Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs, Charles S.
    Tomasek, Jiri
    Yong, Cho Jae
    Dumitru, Filip
    Passalacqua, Rodolfo
    Goswami, Chanchal
    Safran, Howard
    dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David R.
    Melichar, Bohuslav
    Tehfe, Mustapha
    Topuzov, Eldar
    Zalcberg, John Raymond
    Chau, Ian
    Campbell, William
    Sivanandan, Choondal
    Pikiel, Joanna
    Koshiji, Minori
    Hsu, Yanzhi
    Liepa, Astra M.
    Gao, Ling
    Schwartz, Jonathan D.
    Tabernero, Josep
    [J]. LANCET, 2014, 383 (9911) : 31 - 39
  • [9] Gasparini G, 2000, Oncologist, V5 Suppl 1, P37
  • [10] HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series
    Grabsch, Heike
    Sivakumar, Shivan
    Gray, Sally
    Gabbert, Helmut E.
    Mueller, Wolfram
    [J]. CELLULAR ONCOLOGY, 2010, 32 (1-2) : 57 - 65